Thrombolysis in Pediatric Stroke Study

Исследование тромболитической терапии при инсульте у детей
Michael Rivkin, Gabrielle deVeber, Rebecca Ichord, Adam Kirton, Anthony K.C. Chan, Collin A. Hovinga, Joan Cox Gill, Anikó Szabó, Michael D. Hill, Kelley Scholz, Catherine Amlie‐Lefond
2015-01-23

intracranial hemorrhagepediatric stroketPA pharmacokineticsthrombolysistissue plasminogen activator
5] The perceived high potential for benefit after treatment justified assumption of risk for intracranial hemorrhage (ICH) after its use. 9 Because in adults, the risk of hemorrhage after tPA use was thought to be related to infarct volume; this principle was assumed for children. The known developmental trajectory of the fibrinolytic system includes lower levels of endogenous tPA and higher levels of plasminogen activator inhibitor-1 in young children than are found in adults and warranted a dose-finding study beginning at doses lower than that used in adults with incremental increase through the currently used adult dose of 0.9 mg/kg and careful assessment of tPA pharmacokinetics. urrently, information on children treated with tPA consists of case reports, small case series, and hospital database documentation. Best practice for the treatment of children with acute stroke has received little rigorous study. Clinical approach varies widely among centers and reflects a dearth of research on which to base treatment protocols. ]
1
Because hemorrhage risk was assumed to correlate with infarct volume in adults, the same principle was applied to children.
2
Before this study, pediatric tPA evidence consisted mainly of case reports, small case series, and hospital databases, with substantial variation in clinical practice.
3
Developmental differences in fibrinolysis, including lower endogenous tPA and higher plasminogen activator inhibitor-1 levels in young children, motivated pediatric dose-finding.
4
The protocol began below the adult alteplase dose and incrementally increased to 0.9 mg/kg while carefully assessing tPA pharmacokinetics.
5
The study was justified by potential treatment benefits despite the risk of intracranial hemorrhage after thrombolysis in pediatric stroke.

Children with acute ischemic stroke treated with tissue plasminogen activator (tPA)

Safety, dose selection, pharmacokinetics, and clinical treatment practices for tPA thrombolysis, particularly the risk of intracranial hemorrhage (ICH)

Publication Details
Publication Date
2015-01-23
Journal
Publisher
ISSN
Access Type
Author Information
Authors
Michael Rivkin
Gabrielle deVeber
Rebecca Ichord
Adam Kirton
Anthony K.C. Chan
Collin A. Hovinga
Joan Cox Gill
Anikó Szabó
Michael D. Hill
Kelley Scholz
Catherine Amlie‐Lefond
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat
Make a presentation
100%